Lauren Friedman, 23, remembers her first sexual experience not as a milestone but as a moment of disturbing realization: she couldn't feel anything. Months later, during a procedure many find painful, she experienced almost no discomfort, prompting doctors to question if she had given birth, an impossibility for her at 20. This led Friedman to discover a community of individuals experiencing similar persistent sexual issues after taking antidepressant medications, a condition known as post-SSRI sexual dysfunction (PSSD).
PSSD is thought to be triggered by selective serotonin reuptake inhibitors (SSRIs), a common class of antidepressants that includes sertraline (Zoloft), fluoxetine (Prozac), and escitalopram (Lexapro). While sexual side effects such as decreased libido are common and generally resolve after discontinuing SSRIs, PSSD symptoms—including genital numbness, erectile dysfunction, loss of libido, and muted or absent orgasms—reportedly persist for months or years after medication cessation, and may even be permanent. Some individuals also report emotional blunting and a diminished capacity for romantic attraction.
While regulatory bodies in the UK, Europe, and Australia have updated patient information leaflets to warn of persistent sexual dysfunction after SSRI treatment, the U.S. Food and Drug Administration (FDA) has yet to formally acknowledge the condition. The American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) does note that SSRI-induced sexual dysfunction may persist after discontinuation.
Approximately one in ten American adults take antidepressants, with SSRIs being the most frequently prescribed. Early studies suggested a low incidence of sexual side effects, but more recent estimates place the figure closer to 15 percent or higher. The PSSD Network, a support group for sufferers, reports a global membership of 20,000.
Friedman was prescribed sertraline in 2022 for depression and anxiety. While the medication initially helped with intrusive thoughts, she noticed a loss of sexual interest, which her doctor attributed to the drug and expected to resolve after cessation. However, upon stopping the medication, she experienced persistent emotional flatness and a disconnect from the world, alongside her sexual dysfunction.
The exact cause of PSSD remains unclear, though some researchers suggest the drugs may alter brain function. However, some experts caution that depression itself can cause sexual dysfunction, and a definitive biological mechanism for PSSD has not yet been established. Preliminary research has hinted at possible physical changes in erectile tissue among men with the condition.
Many PSSD sufferers report significant distress not only from their symptoms but also from the difficulty in obtaining medical validation. Some are told their symptoms are psychological or impossible after discontinuing medication, leading to prolonged periods of searching for answers. Experts indicate that the FDA may be re-evaluating PSSD and could release a report in the coming months.
Sertraline was originally developed by Pfizer and is now marketed by Viatris, with generic versions produced by multiple companies. A Viatris spokesperson stated that patient safety is a priority and that the company provides information on the appropriate use of sertraline, noting that the prescribing label warns of potential sexual dysfunction during treatment. Friedman expressed anger towards her doctor, who acknowledged knowledge of PSSD but believed it was too rare to affect her, despite having another patient with the condition. She hopes that increased awareness and research will lead to treatments for PSSD, emphasizing the need for patients not to suffer in silence. Healthcare providers urge patients not to stop antidepressant medication without consulting a doctor.